Boston Scientific Co. (NYSE:BSX) SVP Vance R. Brown Sells 4,826 Shares

Boston Scientific Co. (NYSE:BSX - Get Free Report) SVP Vance R. Brown sold 4,826 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. This trade represents a 11.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Boston Scientific Stock Up 0.8 %

Shares of BSX traded up $0.85 during mid-day trading on Friday, hitting $101.99. 2,614,561 shares of the company's stock were exchanged, compared to its average volume of 6,363,665. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $70.97 and a twelve month high of $107.17. The firm has a fifty day moving average of $98.75 and a two-hundred day moving average of $94.69. The stock has a market cap of $150.86 billion, a price-to-earnings ratio of 81.49, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Institutional Trading of Boston Scientific

Several large investors have recently modified their holdings of BSX. TFC Financial Management Inc. grew its stake in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 210 shares during the last quarter. Colonial Trust Co SC grew its position in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific during the 4th quarter worth about $25,000. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Finally, Global Wealth Strategies & Associates grew its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BSX shares. Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. Raymond James boosted their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. UBS Group increased their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Piper Sandler boosted their price target on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Wells Fargo & Company raised their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Boston Scientific has an average rating of "Buy" and an average price target of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.